Trump Administration Launches Drug Discount Website TrumpRx.gov
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: seekingalpha
- Launch of Discount Platform: The Trump administration has unveiled TrumpRx.gov, a website designed to help consumers find discounts on brand-name drugs when paying cash, initially featuring 43 drugs from five companies, with more expected in the coming months.
- Significant Price Reductions: Monthly prices for Novo Nordisk's Ozempic and Wegovy will drop from $1,028 and $1,349 to an average of $350 and as low as $199, with Wegovy pills potentially falling to $149, significantly easing the financial burden on diabetes and obesity patients.
- Coupon Card Availability: The TrumpRx website lists coupon cards for some drugs that can be used at local pharmacies nationwide, although certain specialty medicines are excluded, reflecting the government's efforts to enhance drug accessibility for consumers.
- Future Expansion Plans: The White House indicated that discounts from 11 additional pharmaceutical companies that have agreements with the administration will be available soon, aiming to broaden drug options and improve health outcomes for Americans by lowering drug prices.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRK is 119.53 USD with a low forecast of 95.00 USD and a high forecast of 139.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 118.330
Low
95.00
Averages
119.53
High
139.00
Current: 118.330
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump Administration Launches Drug Discount Website TrumpRx.gov
- Launch of Discount Platform: The Trump administration has unveiled TrumpRx.gov, a website designed to help consumers find discounts on brand-name drugs when paying cash, initially featuring 43 drugs from five companies, with more expected in the coming months.
- Significant Price Reductions: Monthly prices for Novo Nordisk's Ozempic and Wegovy will drop from $1,028 and $1,349 to an average of $350 and as low as $199, with Wegovy pills potentially falling to $149, significantly easing the financial burden on diabetes and obesity patients.
- Coupon Card Availability: The TrumpRx website lists coupon cards for some drugs that can be used at local pharmacies nationwide, although certain specialty medicines are excluded, reflecting the government's efforts to enhance drug accessibility for consumers.
- Future Expansion Plans: The White House indicated that discounts from 11 additional pharmaceutical companies that have agreements with the administration will be available soon, aiming to broaden drug options and improve health outcomes for Americans by lowering drug prices.
See More
TrumpRx Platform Set to Launch Today
- Direct-to-Consumer Platform: The Trump administration's upcoming TrumpRx platform, aimed at offering popular prescription drugs directly to consumers, is set to officially launch today at 7 PM ET, potentially transforming the drug sales model.
- Wide Industry Participation: At least 16 pharmaceutical companies, including Pfizer and AstraZeneca, have entered agreements with the Trump administration to sell drugs via TrumpRx, indicating broad industry support for the platform.
- Diverse Medication Offerings: TrumpRx will provide a variety of medications, including Novo Nordisk's weight-loss drug Wegovy, Eli Lilly's Zepbound, Amgen's cholesterol drug Repatha, and Merck's diabetes medication Januvia, catering to diverse consumer needs.
- Commitment to Price Transparency: The Trump administration aims to lower drug prices by eliminating intermediaries and selling directly to consumers, although it remains uncertain whether this model will genuinely result in cost reductions for cash-paying patients.
See More
Bristol Myers Squibb Reports Strong Q4 Results and Positive 2026 Outlook
- Strong Earnings Report: Bristol Myers Squibb reported fourth-quarter revenue of $12.5 billion, a 1% increase year-over-year, surpassing the $12.28 billion expected by analysts, which enhances investor confidence in the company's stability in drug sales.
- Earnings Beat Expectations: Although earnings per share fell 25% year-over-year to $1.26, it still exceeded estimates of $1.12, reflecting effective cost control and margin improvement strategies that further solidify its market position.
- Optimistic 2026 Outlook: The company forecasts revenue between $46 billion and $47.5 billion for 2026, exceeding the $44.16 billion expected by the market, indicating confidence in future growth, particularly driven by the new drug Cobenfy.
- Cost-Saving Commitment: Bristol Myers is committed to achieving approximately $1 billion in cost savings in 2025 and plans to save another $1 billion over the next two years, which will enhance the company's profitability and competitive edge in the market.
See More
Amazon's Stock Drops Ahead of Earnings Report
- Amazon Earnings Preview: Amazon is set to release its earnings report on Thursday, with its stock dropping 2.4% ahead of the announcement, indicating cautious investor sentiment that may impact short-term market confidence.
- Alphabet's Strong Performance: Alphabet exceeded Wall Street expectations in its fourth-quarter earnings report released on Wednesday, although its stock fell about 1% in after-hours trading; the projected capital expenditures for 2026 are expected to reach between $175 billion and $185 billion, nearly double that of 2025, reflecting a strong commitment to future growth.
- Qualcomm's Disappointing Guidance: Qualcomm reported quarterly earnings that surpassed expectations, yet its stock fell 9% in after-hours trading due to disappointing forward guidance, highlighting investor concerns about future performance, with shares down nearly 13% year-to-date in 2026.
- Strong Consumer Staples Sector: The Consumer Staples Select Sector SPDR ETF (XLP) has risen for four consecutive days, gaining over 1% each day and hitting new highs in the past three sessions, indicating strong performance in 2026 with over 12% growth year-to-date, making it the third-best performing sector in the market.
See More
Wall Street Volatility Highlights Importance of Portfolio Diversification
- Tech Stock Decline: Tech stocks have been severely impacted by recent volatility, with AMD's share price plummeting 17% as investor confidence in the enterprise software sector wanes, highlighting the risks of over-reliance on tech investments.
- Strong Performance of Blue-Chip Stocks: In stark contrast to tech stocks, the Dow Jones Industrial Average rose by 260 points, or 0.5%, indicating that old-economy companies are demonstrating greater resilience during market turmoil, attracting investors seeking stability.
- Winners Across Industries: Companies like Campbell, PepsiCo, Smuckers, and Kraft Heinz have seen their stock prices rise despite the threat of GLP-1, reflecting ongoing consumer demand and confidence in the food sector amidst market fluctuations.
- Recovery in Banks and Industrials: Recent gains in bank stocks and industrials such as Honeywell, Dover, and Emerson Electric suggest that investors believe these firms will benefit from efficiency improvements brought by artificial intelligence, enhancing their investment appeal.
See More
Investors Should Focus on Diversification
- Tech Stock Pullback: Tech stocks have faced significant declines recently, with AMD dropping 17% as investor confidence wanes in the enterprise software sector, highlighting the risks of over-reliance on tech investments.
- Strong Performance in Traditional Sectors: In contrast, the blue-chip Dow Jones Industrial Average rose by 260 points, or 0.5%, indicating that traditional sectors like banking and industrials are attracting investor interest in the current market environment.
- Investment Value in Healthcare: Companies like Johnson & Johnson, Merck, and Amgen have performed well, and despite their stock price increases this year, they are still considered valuable investments relative to the broader market, showcasing the stability and appeal of the healthcare sector.
- Recovery of Banks and Industrials: With growing investor confidence in AI's efficiency improvements, banks and industrial stocks such as Honeywell and Dover have also seen gains recently, reflecting optimistic expectations for these companies' future profitability.
See More
Trump Administration Launches Drug Discount Website TrumpRx.gov
- Launch of Discount Platform: The Trump administration has unveiled TrumpRx.gov, a website designed to help consumers find discounts on brand-name drugs when paying cash, initially featuring 43 drugs from five companies, with more expected in the coming months.
- Significant Price Reductions: Monthly prices for Novo Nordisk's Ozempic and Wegovy will drop from $1,028 and $1,349 to an average of $350 and as low as $199, with Wegovy pills potentially falling to $149, significantly easing the financial burden on diabetes and obesity patients.
- Coupon Card Availability: The TrumpRx website lists coupon cards for some drugs that can be used at local pharmacies nationwide, although certain specialty medicines are excluded, reflecting the government's efforts to enhance drug accessibility for consumers.
- Future Expansion Plans: The White House indicated that discounts from 11 additional pharmaceutical companies that have agreements with the administration will be available soon, aiming to broaden drug options and improve health outcomes for Americans by lowering drug prices.
See More
TrumpRx Platform Set to Launch Today
- Direct-to-Consumer Platform: The Trump administration's upcoming TrumpRx platform, aimed at offering popular prescription drugs directly to consumers, is set to officially launch today at 7 PM ET, potentially transforming the drug sales model.
- Wide Industry Participation: At least 16 pharmaceutical companies, including Pfizer and AstraZeneca, have entered agreements with the Trump administration to sell drugs via TrumpRx, indicating broad industry support for the platform.
- Diverse Medication Offerings: TrumpRx will provide a variety of medications, including Novo Nordisk's weight-loss drug Wegovy, Eli Lilly's Zepbound, Amgen's cholesterol drug Repatha, and Merck's diabetes medication Januvia, catering to diverse consumer needs.
- Commitment to Price Transparency: The Trump administration aims to lower drug prices by eliminating intermediaries and selling directly to consumers, although it remains uncertain whether this model will genuinely result in cost reductions for cash-paying patients.
See More
Bristol Myers Squibb Reports Strong Q4 Results and Positive 2026 Outlook
- Strong Earnings Report: Bristol Myers Squibb reported fourth-quarter revenue of $12.5 billion, a 1% increase year-over-year, surpassing the $12.28 billion expected by analysts, which enhances investor confidence in the company's stability in drug sales.
- Earnings Beat Expectations: Although earnings per share fell 25% year-over-year to $1.26, it still exceeded estimates of $1.12, reflecting effective cost control and margin improvement strategies that further solidify its market position.
- Optimistic 2026 Outlook: The company forecasts revenue between $46 billion and $47.5 billion for 2026, exceeding the $44.16 billion expected by the market, indicating confidence in future growth, particularly driven by the new drug Cobenfy.
- Cost-Saving Commitment: Bristol Myers is committed to achieving approximately $1 billion in cost savings in 2025 and plans to save another $1 billion over the next two years, which will enhance the company's profitability and competitive edge in the market.
See More
Amazon's Stock Drops Ahead of Earnings Report
- Amazon Earnings Preview: Amazon is set to release its earnings report on Thursday, with its stock dropping 2.4% ahead of the announcement, indicating cautious investor sentiment that may impact short-term market confidence.
- Alphabet's Strong Performance: Alphabet exceeded Wall Street expectations in its fourth-quarter earnings report released on Wednesday, although its stock fell about 1% in after-hours trading; the projected capital expenditures for 2026 are expected to reach between $175 billion and $185 billion, nearly double that of 2025, reflecting a strong commitment to future growth.
- Qualcomm's Disappointing Guidance: Qualcomm reported quarterly earnings that surpassed expectations, yet its stock fell 9% in after-hours trading due to disappointing forward guidance, highlighting investor concerns about future performance, with shares down nearly 13% year-to-date in 2026.
- Strong Consumer Staples Sector: The Consumer Staples Select Sector SPDR ETF (XLP) has risen for four consecutive days, gaining over 1% each day and hitting new highs in the past three sessions, indicating strong performance in 2026 with over 12% growth year-to-date, making it the third-best performing sector in the market.
See More
Wall Street Volatility Highlights Importance of Portfolio Diversification
- Tech Stock Decline: Tech stocks have been severely impacted by recent volatility, with AMD's share price plummeting 17% as investor confidence in the enterprise software sector wanes, highlighting the risks of over-reliance on tech investments.
- Strong Performance of Blue-Chip Stocks: In stark contrast to tech stocks, the Dow Jones Industrial Average rose by 260 points, or 0.5%, indicating that old-economy companies are demonstrating greater resilience during market turmoil, attracting investors seeking stability.
- Winners Across Industries: Companies like Campbell, PepsiCo, Smuckers, and Kraft Heinz have seen their stock prices rise despite the threat of GLP-1, reflecting ongoing consumer demand and confidence in the food sector amidst market fluctuations.
- Recovery in Banks and Industrials: Recent gains in bank stocks and industrials such as Honeywell, Dover, and Emerson Electric suggest that investors believe these firms will benefit from efficiency improvements brought by artificial intelligence, enhancing their investment appeal.
See More
Investors Should Focus on Diversification
- Tech Stock Pullback: Tech stocks have faced significant declines recently, with AMD dropping 17% as investor confidence wanes in the enterprise software sector, highlighting the risks of over-reliance on tech investments.
- Strong Performance in Traditional Sectors: In contrast, the blue-chip Dow Jones Industrial Average rose by 260 points, or 0.5%, indicating that traditional sectors like banking and industrials are attracting investor interest in the current market environment.
- Investment Value in Healthcare: Companies like Johnson & Johnson, Merck, and Amgen have performed well, and despite their stock price increases this year, they are still considered valuable investments relative to the broader market, showcasing the stability and appeal of the healthcare sector.
- Recovery of Banks and Industrials: With growing investor confidence in AI's efficiency improvements, banks and industrial stocks such as Honeywell and Dover have also seen gains recently, reflecting optimistic expectations for these companies' future profitability.
See More
